FGAM
BPMC

Financial Gravity Asset Management’s Blueprint Medicines BPMC Stock Holding History

Financial Gravity Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1
Closed – – 1404
2019
Q3 		$0 Buy
+1
New +$86 ﹤0.01% 1207
2018
Q3 		$0 Buy
6
+2
+50% +$139 ﹤0.01% 1398
2018
Q2 		$0 Buy
+4
New +$318 ﹤0.01% 1415

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Financial Gravity Asset Management's BPMC Position: Q4 2019 in Review

Financial Gravity Asset Management sold out of Blueprint Medicines (BPMC) in Q4 2019, closing a stake of 1 share.

Financial Gravity Asset Management first reported a position in BPMC in Q2 2018 and held it in 3 quarters. The position peaked at $0 in Q3 2019. 228 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

  • Financial Gravity Asset Management reported no remaining Blueprint Medicines position as of Q4 2019 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Blueprint Medicines share in Q4 2019.
  • Financial Gravity Asset Management first reported a position in Blueprint Medicines in Q2 2018 and held it in 3 quarters.
  • Financial Gravity Asset Management's Blueprint Medicines position peaked at $0 in Q3 2019.
  • 228 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Financial Gravity Asset Management's 13F filing for Q4 2019, filed 28 Feb 2020.